Derek Archila is ranked #2312 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Derek Archila (Wells Fargo) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Derek Archila's stock ratings?

About 43% of Derek's ratings were profitable over a one-year hold, with an average return of +3.4% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Derek Archila

Derek Archila

Wells Fargo

Wall Street Analyst

★★☆☆☆

#2312

on 13Foresight · ranked by our own returns

43%

Success Rate

+3.4%

Average Return

25 of 58 calls profitable · -3.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 43% of Derek Archila's ratings turned a profit when each position was held for 1 year — averaging +3.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

134 Buy 50 Hold 3 Sell

Derek's Stock Coverage 59 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ARGX Argenx Se	Jun 17, 2026	BUY	Strong Buy -15.9% avg upside 46 analysts	$1291.00 47.01% Upside	·
SEPN Septerna, Inc.	Jun 17, 2026	BUY	Strong Buy +18.2% avg upside 12 analysts	$48.00 32.80% Upside	·
RYTM Rhythm Pharmaceuticals	Jun 17, 2026	BUY	Strong Buy +25.2% avg upside 19 analysts	$155.00 60.22% Upside	+0.0%
INCY Incyte	Jun 17, 2026	HOLD	Buy +1.0% avg upside 47 analysts	$101.00 2.83% Upside	+0.0%
ASND Ascendis Pharma	Jun 17, 2026	BUY	Strong Buy +17.0% avg upside 24 analysts	$326.00 41.28% Upside	·
VRDN Viridian Therapeutics	Jun 17, 2026	HOLD	Strong Buy +103.7% avg upside 32 analysts	$20.00 20.33% Upside	·
ORIC Oric Pharmaceuticals	Jun 11, 2026	BUY	Strong Buy +180.3% avg upside 19 analysts	$25.00 194.39% Upside	+5.8%
NRIX Nurix Therapeutics	Jun 09, 2026	HOLD	Strong Buy +75.6% avg upside 26 analysts	$25.00 42.38% Upside	·
TRAX First Tracks Biotherapeutics Inc	Jun 08, 2026	BUY	Strong Buy +113.2% avg upside 7 analysts	$30.00 72.18% Upside	·
ARVN Arvinas Holding Company	May 22, 2026	BUY	Buy +264.5% avg upside 27 analysts	$15.00 95.49% Upside	-16.6%
IMVT Immunovant	May 21, 2026	BUY	Strong Buy +8.9% avg upside 24 analysts	$45.00 27.24% Upside	+1.7%
ATYR aTyr Pharma	May 18, 2026	HOLD	Buy +2023.9% avg upside 17 analysts	$1.00 121.91% Upside	·
ALMS Alumis Inc.	May 15, 2026	BUY	Strong Buy +63.6% avg upside 11 analysts	$51.00 117.76% Upside	+0.8%
CLDX Celldex	May 13, 2026	BUY	Strong Buy +20.6% avg upside 28 analysts	$54.00 66.53% Upside	-0.5%
CCCC C4 Therapeutics	May 13, 2026	BUY	Strong Buy +330.3% avg upside 19 analysts	$10.00 140.94% Upside	-3.3%
KYTX Kyverna Therapeutics, Inc.	May 12, 2026	BUY	Strong Buy +238.7% avg upside 7 analysts	$33.00 308.91% Upside	-21.4%
BBIO BridgeBio Pharma	May 09, 2026	BUY	Strong Buy +38.7% avg upside 34 analysts	$98.00 47.87% Upside	+4.2%
EXEL Exelixis	Apr 14, 2026	HOLD	Strong Buy -21.0% avg upside 33 analysts	$35.00 32.61% Downside	+15.8%
ANNX Annexon Biosciences	Apr 01, 2026	BUY	Strong Buy +181.2% avg upside 13 analysts	$27.00 451.09% Upside	-4.5%
ALXO ALX Oncology Holdings	Mar 19, 2026	BUY	Strong Buy +1072.8% avg upside 11 analysts	$5.00 226.87% Upside	-33.8%
GLUE Monte Rosa Therapeutics	Mar 18, 2026	BUY	Strong Buy +27.5% avg upside 14 analysts	$29.00 58.45% Upside	+16.2%
QTTB Q32 Bio	Mar 11, 2026	HOLD	Buy +345.2% avg upside 24 analysts	$10.00 15.97% Downside	-20.4%
IRON Disc Medicine	Mar 02, 2026	BUY	Strong Buy +20.2% avg upside 21 analysts	$79.00 11.57% Upside	+5.3%
KYMR Kymera Therapeutics	Mar 02, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	$116.00 28.23% Upside	-0.2%
ALNY Alnylam Pharma	Jan 20, 2026	HOLD	Strong Buy +23.6% avg upside 51 analysts	$376.00 35.13% Upside	-20.4%
ANAB AnaptysBio	Dec 16, 2025	BUY	Strong Buy +26.1% avg upside 26 analysts	$81.00 40.85% Upside	+91.9%
CQP Cheniere Energy Partners	Dec 16, 2025	SELL	Sell -10.6% avg upside 24 analysts	$56.00 3.54% Downside	-16.2%
PTCT PTC Therapeutics	Oct 17, 2025	BUY	Buy -1.5% avg upside 29 analysts	$73.00 7.62% Downside	+19.1%
TECX Tectonic Therapeutic	Oct 17, 2025	BUY	Strong Buy +88.0% avg upside 24 analysts	$101.00 236.50% Upside	+61.6%
LQDA Liquidia Technologies	Oct 17, 2025	BUY	Strong Buy -28.5% avg upside 15 analysts	$31.00 56.41% Downside	+205.4%
STRO Sutro Biopharma	Aug 12, 2025	HOLD	Strong Buy +31.6% avg upside 20 analysts	$30.00 1.20% Upside	+269.2%
CABA Cabaletta Bio	Aug 08, 2025	HOLD	Strong Buy +390.0% avg upside 16 analysts	$2.00 29.55% Downside	+143.4%
ZYME Zymeworks	Aug 07, 2025	HOLD	Strong Buy +40.3% avg upside 25 analysts	$14.00 39.54% Downside	+85.0%
ZNTL Zentalis Pharmaceuticals	Aug 06, 2025	HOLD	Buy +292.3% avg upside 16 analysts	$5.00 35.15% Upside	+159.4%
TSE:WEED Canopy Growth	Dec 06, 2021	SELL	Hold +1298.4% avg upside 23 analysts	$11.33 721.05% Upside	·
SMG Scotts Miracle-Gro Company	Dec 06, 2021	BUY	Strong Buy +25.2% avg upside 11 analysts	$180.00 178.34% Upside	-60.7%
EQ Equillium	Jun 13, 2021	BUY	Strong Buy +181.9% avg upside 14 analysts	$12.00 293.49% Upside	-66.3%
RNAC Cartesian Therapeutics	May 13, 2021	HOLD	Strong Buy +228.2% avg upside 19 analysts	$3.00 68.86% Downside	-75.1%
URGN Urogen Pharma	May 13, 2021	BUY	Strong Buy +13.0% avg upside 16 analysts	$30.00 10.56% Downside	-61.3%
HRTX Heron Therapeutics	May 13, 2021	BUY	Strong Buy +6404.5% avg upside 21 analysts	$27.00 6367.12% Upside	-76.9%
LKFT Lakefront Biotherapeutics	May 09, 2021	HOLD	Hold +272.6% avg upside 24 analysts	$97.00 242.81% Upside	·
MDGL Madrigal Pharmaceuticals	May 06, 2021	HOLD	Strong Buy -5.8% avg upside 31 analysts	$130.00 74.32% Downside	-49.0%
ESPR Esperion	May 04, 2021	HOLD	Buy +701.2% avg upside 22 analysts	$20.00 534.93% Upside	-75.1%
DBVT DBV Technologies SA - American	May 03, 2021	HOLD	Strong Buy +55.4% avg upside 15 analysts	$6.00 61.34% Downside	-79.3%
AMRN Amarin	Apr 29, 2021	HOLD	Buy -47.3% avg upside 18 analysts	$6.00 62.59% Downside	-48.7%
VKTX Viking Therapeutics	Apr 28, 2021	BUY	Strong Buy +141.1% avg upside 30 analysts	$13.00 57.22% Downside	-62.0%
FR:IVA Inventiva	Mar 05, 2021	BUY	Strong Buy +476.8% avg upside 5 analysts	$16.55 441.91% Upside	·
IVA Inventiva	Mar 05, 2021	BUY	Strong Buy +350.1% avg upside 16 analysts	$19.00 432.22% Upside	-20.1%
GB:0QW0 arGEN X	Mar 04, 2021	HOLD	Strong Buy -24.9% avg upside 24 analysts	$290.11 62.28% Downside	·
NL:LKFT Galapagos	Feb 19, 2021	HOLD	Sell +112.9% avg upside 16 analysts	$96.00 290.25% Upside	·
FR:GNFT Genfit	Sep 30, 2020	BUY	Strong Buy +181.4% avg upside 5 analysts	$11.00 3.20% Upside	·
PCRX Pacira Pharmaceuticals	Jul 10, 2020	HOLD	Buy +74.3% avg upside 21 analysts	—	-1.5%
VNDA Vanda	Jul 10, 2020	HOLD	Strong Buy +254.2% avg upside 13 analysts	—	+78.6%
ZVRA Zevra Therapeutics	Apr 02, 2018	BUY	Strong Buy +85.3% avg upside 15 analysts	$13.00 0.82% Upside	-72.9%
TRVN Trevena	Mar 22, 2018	BUY	Buy +128278.4% avg upside 11 analysts	—	·
PRGO Perrigo Company	Mar 05, 2018	BUY	Buy +565.5% avg upside 20 analysts	$98.00 856.01% Upside	-39.2%
TEVA Teva Pharmaceutical	Feb 08, 2018	HOLD	Buy -6.6% avg upside 39 analysts	—	-2.2%
TPST Tempest Therapeutics	Nov 09, 2017	HOLD	Buy +1669.9% avg upside 18 analysts	—	-47.9%
VTRS Viatris	Oct 03, 2017	HOLD	Buy +48.4% avg upside 21 analysts	—	+12.5%

🔒 54 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Derek Archila — Frequently Asked Questions

How accurate are Derek Archila's stock ratings?

Based on the calls 13Foresight could measure, about 43% of Derek's ratings were profitable over a one-year hold, with an average return of +3.4% per rating, or -3.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Derek ranked on 13Foresight?

Derek Archila is currently ranked #2312 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Derek cover?

Derek most recently has ratings on ARGX, SEPN, RYTM, INCY, ASND, VRDN, ORIC, NRIX, TRAX, ARVN, IMVT, ATYR and 47 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!